Adage Capital Partners Gp, L.L.C. Protagonist Therapeutics, Inc Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,092,262 shares of PTGX stock, worth $59.6 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
1,092,262
Previous 343,504
217.98%
Holding current value
$59.6 Million
Previous $16.6 Million
263.43%
% of portfolio
0.11%
Previous 0.03%
Shares
24 transactions
Others Institutions Holding PTGX
# of Institutions
295Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$337 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$314 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$314 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$238 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$177 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.68B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...